問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,343

    Total Beds

  • 801

    Total Doctors

  • n123987ctc@gmail.com
  • Hsin-Pin Tu
  • 06-2353535#4691
  • 704Tainan CityTainan NorthNo.138,Sheng Li Road,Tainan, Taiwan

Recruiting Trial

767Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1613Cases

2009-10-01 - 2012-01-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Study ended10Sites

2011-12-07 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-09-01 - 2013-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-04-15 - 2013-03-31

Phase I

A phase I dose escalation trial of weekly intravenous administrations of BI 836845 in patients with advanced solid cancers with repeated administrations in patients showing clinical benefit

  • Condition/Disease

    advanced solid cancer

  • Test Drug

    BI 836845

Participate Sites
3Sites

Terminated3Sites

2011-09-01 - 2018-12-31

Phase III

A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk.

  • Condition/Disease

    type 2 diabetes

  • Test Drug

    Linagliptin

Participate Sites
16Sites

Terminated16Sites

2010-09-01 - 2012-07-01

Phase III

A phase III randomized, double-blind, placebo-controlled, parallel trial to evaluate BI 10773 (10 mg, 25 mg) orally once a day for a 24 week course of treatment after treatment with Metformin or combined Metformin and Sulfonylurea Efficacy and safety of type 2 diabetes patients with poor blood glucose control

  • Condition/Disease

    Type 2 or unspecified diabetes

  • Test Drug

    BI 10773

Participate Sites
9Sites

Terminated9Sites

2011-05-01 - 2013-06-30

Phase III

A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (incl. 24 weeks of preceding trial) as monotherapy or with different back-ground therapies in patients with type 2 diabetes mellitus previously completing trial 1245.19, 1245,20 or 1245.23.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    BI 10773

Participate Sites
9Sites

Terminated9Sites

2015-11-01 - 2017-10-31

Phase III

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

  • Condition/Disease

    Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

  • Test Drug

    ASP8273

Participate Sites
9Sites

Terminated9Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-01-01 - 2020-06-30

Phase III

A Phase 3 Multicenter, Randomized, Double-blind,Placebo-controlled Study with an Open Label Extension to Evaluatethe Efficacy and Safety of KHK4827 in Subjects with Axial Spondyloarthritis

  • Condition/Disease

    Axial Spondyloarthritis

  • Test Drug

    KHK4827 (Brodalumab)

Participate Sites
13Sites

Terminated11Sites

羅淑芬
Linkou Chang Gung Medical Foundation

黃春明
China Medical University Hospital-Taipei

未分科

2009-08-01 - 2012-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 153 154 155 156 157 162
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB